Bellevue Life Sciences Acquisition Corp - BLAC STOCK NEWS

Bellevue Life Sciences Acquisition Corp. (BLAC) has received stockholder approval for its business combination with OSR Holdings Co., The transaction is expected to close on February 14, 2025, following foreign investment approval from the Industrial Bank of Korea. The company has changed its name to OSR Holdings, Inc. and will trade on Nasdaq under symbols 'OSRH' and 'OSRHW' starting February 18, 2025.

Post-transaction, OSR Holdings will own approximately 67% of OSR Holdings Co., , with agreements in place to acquire an additional 22% of shares through put/call provisions beginning in 2026. The company's portfolio includes a Phase 2 clinical stage company developing immunotherapies for oncology, an early clinical stage company focusing on degenerative diseases, and a medical device distributions company operating across the US, Europe, and South Korea.

Bellevue Life Sciences Acquisitions Corp. (BLAC) has announced a Special Meeting to vote on extending the deadline for a business combination with OSR Holdings Co., , a healthcare holding company based in South Korea. Stockholders are encouraged to vote in favor of the Extension Amendment Proposal to extend the deadline from May 14, 2024, to November 14, 2024. Failure to secure at least 65% of votes may lead to liquidation and missed opportunities for stockholders.

OSR Holdings and SillaJen have signed a Memorandum of Understanding to collaborate on developing innovative therapeutics and entering the U.S. market. OSR Holdings, a global healthcare holding company, will partner with SillaJen, a biotech firm known for its immuno-oncology drug candidates, to share technology and resources. The collaboration aims to create synergies between their technologies and new drug candidates, focusing on the advancement of new drug assets and technological innovations.

OSR Holdings and SillaJen have signed an MOU to collaborate on innovative therapeutics and enter the U.S. market. OSR Holdings is a global healthcare holding company, while SillaJen is a biotech firm with immuno-oncology drug candidates. The collaboration aims to share technology and resources to create synergies and advance new drug assets. OSR Holdings' portfolio includes Vaximm AG, Darnatein, and RMC. SillaJen's pipeline includes SJ-600 series and BAL0891, focusing on anti-cancer viruses. The partnership signifies a strategic move into the global immuno-oncology market, particularly in the U.S., the largest pharmaceutical market worldwide.

Bellevue Life Sciences Acquisition Corp. (Nasdaq: BLAC) and OSR Holdings Co., Ltd. announced a business combination agreement. Upon closing, outstanding shares of OSR Holdings will be exchanged for BLAC common stock. BLAC will own at least 60% of OSR Holdings and change its name to OSR Biosciences, Inc. Founded in 2019, OSR Holdings is a global healthcare holding company with subsidiaries in biopharmaceutical and medical device sectors. BLAC intends to list its common stock and warrants on Nasdaq Capital Market under new ticker symbols.

Bellevue Life Sciences Acquisition Corp. (BLAC) and OSR Holdings, Ltd. have signed a non-binding letter of intent to complete a business combination in Q4 2023, resulting in OSR Holdings becoming a publicly traded company. The surviving company will be renamed as OSR Biosciences, Inc.